Di-(2-Ethylhexyl)-Phthalate (DEHP) Causes Impaired Adipocyte Function and Alters Serum Metabolites by Klöting, Nora et al.
RESEARCH ARTICLE
Di-(2-Ethylhexyl)-Phthalate (DEHP) Causes
Impaired Adipocyte Function and Alters
SerumMetabolites
Nora Klöting1, Nico Hesselbarth2, Martin Gericke3, Anne Kunath4, Ronald Biemann5,
Rima Chakaroun2, Joanna Kosacka2, Peter Kovacs1, Matthias Kern2, Michael Stumvoll1,2,
Bernd Fischer6, Ulrike Rolle-Kampczyk7, Ralph Feltens7, Wolfgang Otto7, Dirk
K. Wissenbach7, Martin von Bergen7,8,9, Matthias Blüher1,2*
1 IFB AdiposityDiseases, University of Leipzig, Leipzig, Germany, 2 Department of Medicine, University of
Leipzig, Leipzig, Germany, 3 Institute of Anatomy, University of Leipzig, Leipzig, Germany, 4 German
Center for Diabetes Research (DZD), Leipzig, Germany, 5 Institute for Clinical Chemistry, Otto-von-
Guericke-University Magdeburg, Magdeburg, Germany, 6 Department of Anatomy and Cell Biology, Martin
Luther University Halle, Halle (Saale), Germany, 7 Department of Metabolomics, Helmholtz Centre for
Environmental Research Leipzig, Leipzig, Germany, 8 Department of Proteomics, Helmholtz Centre for
Environmental Research Leipzig, Leipzig, Germany, 9 Department of Biotechnology and Environmental
Engineering, University of Aalborg, Aalborg, Denmark
* bluma@medizin.uni-leipzig.de
Abstract
Di-(2-ethylhexyl)-phthalate (DEHP), an ubiquitous environmental contaminant, has been
shown to cause adverse effects on glucose homeostasis and insulin sensitivity in epidemio-
logical studies, but the underlying mechanisms are still unknown. We therefore tested the
hypothesis that chronic DEHP exposure causes impaired insulin sensitivity, affects body
weight, adipose tissue (AT) function and circulating metabolic parameters of obesity resis-
tant 129S6 mice in vivo. An obesity-resistant mouse model was chosen to reduce a poten-
tial obesity bias of DEHP effects on metabolic parameters and AT function. The metabolic
effects of 10-weeks exposure to DEHP were tested by insulin tolerance tests and quantita-
tive assessment of 183 metabolites in mice. Furthermore, 3T3-L1 cells were cultured with
DEHP for two days, differentiated into mature adipocytes in which the effects on insulin
stimulated glucose and palmitate uptake, lipid content as well as on mRNA/protein expres-
sion of key adipocyte genes were investigated. We observed in female mice that DEHP
treatment causes enhanced weight gain, fat mass, impaired insulin tolerance, changes in
circulating adiponectin and adipose tissue Pparg, adiponectin and estrogen expression.
Serum metabolomics indicated a general increase in phospholipid and carnitine concentra-
tions. In vitro, DEHP treatment increases the proliferation rate and alters glucose uptake in
adipocytes. Taken together, DEHP has significant effects on adipose tissue (AT) function
and alters specific serum metabolites. Although, DEHP treatment led to significantly
impaired insulin tolerance, it did not affect glucose tolerance, HOMA-IR, fasting glucose,
insulin or triglyceride serum concentrations. This may suggest that DEHP treatment does
not cause impaired glucose metabolism at the whole body level.
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Introduction
Obesity is the fastest growing health problem in Europe and worldwide. Overweight affects
between 30% and 80% of adults in the WHO European Region and up to one third of children
[1]. In addition to genetic factors, life style factors such as excessive caloric intake, high fat
diets, and low physical activity contribute to obesity. However, there is also increasing evidence
that environmental pollutants including endocrine-disrupting chemicals may contribute to the
development of obesity and metabolic disorders [2]. Chronic exposure to endocrine-disrupting
chemicals such as dioxins [3] bisphenol A [4] or phthalates [5,6] has been linked to an
increased risk of developing insulin resistance or diabetes. Importantly, in the Prospective
Investigation of the Vasculature in Uppsala Seniors Study of 1,016 elderly (age>70 years), Lind
and coworkers demonstrated that several phthalate metabolites are related to diabetes preva-
lence, as well as to markers of insulin secretion and resistance [7].
Among those environmental factors, the plasticizer di(2-ethylhexyl)phthalate (DEHP), has
been reported to induce glucose intolerance and alterations in hepatic glycogen content in rats.
DEHP improves flexibility of polyvinyl chloride [8]. Humans are widely exposed to DEHP,
because it is used in many daily products, including vinyl flooring, wall covering, plastic bags
and covers, food containers, cosmetics, and toys [9]. Humans are exposed to these compounds
through ingestion, inhalation and dermal exposure throughout their entire life, including intra-
uterine life. Although they are readily degraded, phthalates can cross the placenta and DEHP is
consistently found in higher concentrations in children than in adults [10].
DEHP acts as an endocrine disruptor with toxic effects on reproductive and developmental
processes [10]. Despite its widespread industrial use and presence as environmental contami-
nant, there are only a few reports on the effects of DEHP on adipose tissue function and insulin
sensitivity [11–13,6].
In rats, DEHP promoted proliferation and induced hepatomegaly [14]. Liver enlargement
was associated with a decrease in the activity of mitochondrial enzymes and modified the
response to xenobiotics [14]. These effects on the liver are also reflected by alterations in the
serum profiles of amino acids and phosphatidylcholines found in rats after DEHP-exposure
[15]. In general, targeted and quantitative serum metabolomics have been proven to provide
functional insights especially with regard to development and progress of metabolic diseases
[16]. In another study, DEHP-fed rats had altered glucose tolerance associated with abnormal
glucose intermediary metabolite content in liver and skeletal muscle; animals presented with a
deficiency in glucose transport and a reduction in glycogen synthesis [17]. Moreover, Hong
and co-workers hypothesized that oxidative stress caused by exposure to environmental chemi-
cals plays a role in the pathogenesis of metabolic syndrome or type 2 diabetes mellitus by
affecting insulin resistance [18].
In order to test the hypothesis that DEHP may impair insulin sensitivity, we exposed obesity
resistant 129S6 mice to 2% DEHP for 10 weeks and assessed whole body insulin sensitivity and
serum metabolomics. To investigate in more detail the role of DEHP on adipose tissue function
in vitro, we used 3T3-L1 cells and measured proliferation, differentiation, glucose and lipid
uptake as well as insulin sensitivity.
Material and Methods
Animals, diets, insulin tolerance test, and food intake
All animal experiments were performed in accordance with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health (NIH Publication No.
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85–23, revised 1996) and were approved by the local authorities of the state of Saxony, Ger-
many as recommended by the responsible local animal ethics review board (TVV08/09).
In 2007, breeding pairs from Taconic Farms, Inc. (129S6/SvEvTac; Hudson, New York,
USA) were obtained and bred in our animal facility under standardized environmental condi-
tions. Experiments were conducted on male and female of obesity resistant inbred 129S6 (F28)
mice from our own Animal Laboratory at the University of Leipzig, Germany. Mice were kept
acclimatized at 22°C ± 2°C and with a 12-hour light-dark cycle, as well as free access to food
and water. At an age of 11 weeks, mice were randomly divided into two groups and fed ‘ad libi-
tum’ either a standard chow (control group, N = 16, 8 male/8 female) or the same standard diet
supplemented with 0.05mg/kg body weight/day DEHP (DEHP group N = 16, 8 male/8 female)
over a 10weeks experimental feeding period. This DEHP dose level is relevant to human expo-
sure [19]. Food intake and body weight were carefully monitored and measured in both groups
of animals throughout the entire experimental period. From twice a week measurements, food
intake per animal, day and per body weight was calculated for the entire study period and
shown for the measurements in weeks 5 and 6. The insulin tolerance test was performed after 6
weeks of treatment with standard chow alone or supplemented DEHP. Insulin (0.75U per kg
body weight) was injected intraperitoneally. Tail vein blood was taken for glucose measure-
ments at different time points at 0, 15, 30 and 60 minutes after insulin injection. i.p. GTT was
performed in female mice after 8 weeks of treatment as previously described [20]. Homeostatic
model assessment (HOMA) is a method for assessing β-cell function and insulin resistance
(IR) from basal (fasting) glucose and insulin or C-peptide concentrations. HOMA-IR was cal-
culated from basal (fasting) glucose and insulin concentrations from 6 female animals per
experimental group at the end of observation period (10 weeks). At the end of observation
period (10 weeks) whole body composition (fat mass, lean mass and total body water) was
determined in awake mice by using nuclear magnetic resonance technology with
EchoMRI700™ instrument (Echo Medical Systems, Houston, TX, USA) in control and DEHP
treated mice. 6 animals per treatment group were measured. Data were analyzed by the manu-
facturer’s software.
Mice were placed in placed in metabolic cages (Tecniplast S.p.A. Buguggiate, Italy) to sepa-
rate urine and feces over a period of 2 days. Mice had free access to food (standard chow) and
water. At the end of 2 days urine samples were taken to quantify phthalates.
Analytical procedures
Blood glucose values were determined from whole venous blood samples using an automated
glucose monitor (FreeStyle mini, Abbott GmbH, Ludwigshafen, Germany). Insulin, estra-
diol, progesteron and adiponectin serum concentrations were measured by ELISA using mouse
standards according to the manufacturer’s guidelines (Mouse/Rat Insulin ELISA; CrystalChem.
Inc, Downers Grove, IL), (Mouse/Rat Estradiol ELISA; Calbiotech Inc, Spring Valley, CA),
(Mouse/Rat Progesterone ELISA; BioVendor, Karasek, Czech Republic) and (Mouse Adipo-
nectin ELISA; AdipoGen Inc, Incheon, Korea). Serum concentrations of triglycerides and total
cholesterol were analyzed by an automatic chemical analyzer in our Institute of Laboratory
Medicine and Clinical Chemistry.
Quantification of phthalates in urine
100μl urine aliquots were buffered with NaADA (sodium N-(2-acetamido)iminodiacetate, pH
6.6, final concentration 150mM), spiked with 13C4-labelled mono-(2-ethylhexyl)phthalate
(MEHP), mono-(2-ethyl-5-hydroxyhexyl)phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl)
phthalate (MEOHP), mono-(2-ethyl-5-carboxypentyl)phthalate (MECPP),
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methylumbelliferone (MeUmb) and not isotopically labelled methylumbelliferyl glucuronide
(final concentrations 9.5ng/ml each) and subjected to deglucuronation for 5h at 37°C (0.5U
deglucuronidase / arylsulfatase, Helix pomatiae, Roche). Reactions were stopped by acidifica-
tion (formic acid, final concentration 0.5M). Purification of samples was performed via solid
phase extraction (Isolute C18 columns, 200 mg, Biotage). Eluted and vacuum-dried analytes
were resuspended in 100μl 35% acetonitrile. For LC-MS/MS quantification 10 μl aliquots were
separated on a UPLC System (UltiMate™ 3000 RSLC, Thermo scientific, MA, USA) via
reversed phase chromatography (Acquity UPLC BEH C18, 1.7μm, 2.1mm x 100mm, Waters,
Corporation, Milford, USA). Detection and quantification of analytes was achieved on a triple
quadrupole mass spectrometer (Q-Trap 5500, AB Sciex) via electrospray ionisation (350°C,
4500 V, negative mode) using scheduled multi reaction monitoring (MRM) (phthalate analyte
transitions. Absolute concentrations of analytes were calculated with respect to the known con-
centrations of the isotopically labelled standards and previously obtained calibration curves
(quantification software Analyst, AB Sciex).
Serummetabolome analysis
The metabolome analyses were carried out with the AbsoluteIDQ1 p180 Kit (Biocrates Life
Science AG, Innsbruck, Austria). The kit identifies and quantifies 188 metabolites from 5 com-
pound classes, namely acyl carnitines (40), proteinogenic and modified amino acids (19), gly-
cerophospho- and sphingolipids (76 phosphatidylcholines, 14 lysophosphatidylcholines, 15
sphingomyelines), biogenic amines (19) and hexoses. 10μL serum samples were mixed with
isotopically labeled internal standards were derivatized with phenylisothiocyanate and
extracted. For LC-MS analysis of biogenic amines and amino acids and flow injection analysis-
MS/MS measurements (FIA-MS/MS) were used two different dilutions. Both types of measure-
ments were performed on a QTRAP mass spectrometer applying electrospray ionization (ESI)
(ABI Sciex API5500Q-TRAP). The MS was coupled to an UPLC (Waters Acquity, Waters Cor-
poration, Milford, USA). In case of LC-MS the metabolites were separated by an hyphenated
reverse phase column (Agilent, Zorbax Eclipse XDB C18, 3.0 x 100mm, 3.5μm, Agilent Wald-
bronn, Germany) preceded with a precolumn (Security Guard, Phenomenex, C18, 4 x 3mm;
Phenomenex, Aschaffenburg, Germany) applying a gradient. Identification and quantification
were achieved by MRM standardized by applying spiked-in isotopically labelled standards in
positive and negative mode, respectively. For calibration a calibrator mix consisting of 7 differ-
ent concentrations was used. Quality controls were included for 3 different concentration lev-
els. For FIA an isocratic method was used. The integrated MetIDQ software (Biocrates,
Innsbruck, Austria) streamlines data analysis by automated calculation of metabolite concen-
trations providing quality measures and quantification.
Statistical analyses of metabolome data was based on the standard-evaluation of the Bio-
crates software and the manual adjustments, we performed pairwise group comparisons. For
each group and each analyte covered by the Biocrates kit, we calculated the fold change
together with the corresponding significance. The fold change is defined as the ratio between
the mean of the analyte values of first group and the mean of the analyte values of the second
group. The significance is calculated by a two-sample Wilcoxon test with the alternative
hypothesis that the true difference in means is not equal to 0. Fold changes above 3/2 or below
2/3 with a corresponding p-value below 0.05 where considered significant.
Cell culture
Mouse 3T3-L1 adipocytes cell line (genotype XX; ATCC1 CL-173™, American Type Culture
Collection, Rockville, MD) were cultured with 0.01% DEHP for two days and differentiated
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into mature adipocytes as described previously [21]. Briefly, preadipocytes were grown to con-
fluence in DMEM cell culture medium containing 25mM glucose (DMEM-H), 10% fetal
bovine serum, and antibiotics (culture medium). After this period, cells were induced for 3
days in culture medium further supplemented with 1μM insulin, 0.5mM isobutylmethyl-
xanthine, and 0.1μM dexamethasone. Subsequently, they were grown for 3 days in culture
medium with 1μM insulin and for additional three to six more days in culture medium. Vari-
ous effectors were added to cells starved in DMEM-H only for the indicated periods of time. At
the time of the stimulation experiments, at least 95% of the cells had accumulated fat droplets.
Measurements of glucose transport, palmitic acid incorporation and
triglyceride content
In fully differentiated 3T3-L1 adipocytes, basal and insulin-stimulated glucose transport was
measured using 2-deoxyglucose. Eight days after induction, 3T3-L1 adipocytes plated on 24
-well culture dishes were serum starved overnight. Cells were washed twice with Krebs-Ringer
Hepes buffer at 37°C (20mmol/l HEPES, pH 7.4, 136mmol/l NaCl, 4.7mmol/l KCl, 1.25mmol/l
MgSO4, 1.25mmol/l CaCl2) containing 0.1% BSA. The wash buffer was replaced with fresh
Krebs-Ringer Hepes buffer and half of the wells were stimulated with 100nmol/l insulin
(Roche, Basel, Schweiz) at 37°C for 30 minutes. The assay was initiated by adding 2-[3H]
deoxy-D-glucose up to a final concentration of 0.5 μCi for 4 minutes at 37°C. The assay was
terminated by adding 100μM 2-deoxyglucose (Sigma-Aldrich, St. Louis, MO, USA). After
washing the cells with ice-cold PBS, adipocytes were detached from cell culture plates by using
0.1% SDS. Incorporated radioactivity was determined by scintillation counting and adjusted to
protein concentration (BCA Protein Assay Kit, Thermo Fisher Scientific, Rockford, USA).
In addition, uptake of palmitic acid into 3T3-L1 cells was estimated by a [1-14C] palmitic
acid based assay (Perkin Elmer, Massachusetts, USA). Fatty acid stock solution (8mM) was
prepared by dissolving the sodium salt in BSA (3.3mM) solution. Eight days after induction of
adipogenesis, 3T3-L1 adipocytes (on 24-well culture dishes) were washed once with Krebs-
Ringer Hepes buffer at 37°C (20 mmol/l HEPES, pH 7.4, 120mmol/l NaCl, 6.0mmol/l KCl,
1.2mmol/l MgSO4, 1mmol/l CaCl2, 1.2mmol/l KH2PO4) containing 0.1% BSA and incubated
for 2 hours at 37°C in DMEM-H medium containing 1% BSA. After rewashing three times
using Krebs-Ringer HEPES buffer containing 0.1% BSA, 1 ml of Krebs buffer (0.002% BSA)
was applied to each well and radioactive uptake was started by adding 14C-palmitic acid up to a
final concentration of 0.5μCi for 5 minutes at 37°C. Some wells were treated with 5μM of the
fatty acid solution only to measure background activity. The assay was terminated by washing
the cells with ice cold Krebs-buffer and detaching adipocytes from cell culture plates with 0, 1%
SDS. Incorporated radioactivity was determined by scintillation counting and adjusted to pro-
tein concentration. Triglyceride content was determined using the LabAssay Triglyceride
(WAKO Pure Chemicals, Kyoto, Japan).
mRNA expression and western blot analysis
The mRNA expression of key genes, adiponectin, Phosphoinositide 3-kinase (Pi3k), insulin
growth factor receptor 1 (Igf1r) and vesicle-associated membrane protein 4 (Vamp4) in adipose
tissue function was measured using RT-PCR. RNA isolation and quantitative real-time PCR
was performed as previously described [22]. In brief, mRNA expression was measured in a
fluorescence temperature cycler using the TaqMan assay; fluorescence was detected on an ABI
PRISM 7500 sequence detector (Applied Biosystems, Darmstadt, Germany). Total RNA was
isolated using Trizol (Life Technologies, Grand Island, NY, USA), and 1 μg RNA was reverse
transcribed with standard reagents (Life Technologies). From each RT-PCR, 1 μl was amplified
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in a 20 μl PCR reaction using Power Sybr Green Master Mix (ABI, Foster City, CA USA)
according to the manufacturer’s protocol. Samples were incubated in the sequence detector for
an initial denaturation at 95°C for 10 min, followed by 40 PCR cycles, each cycle consisting of
95°C for 15 s, 60°C for 30 s and 72°C for 32 seconds. mRNA level of adiponectin, phospho-ini-
sitol 3 kinase (Pi3k), insulin growth factor receptor 1 (Igf1r) and vesicle-associated membrane
protein 4 (Vamp4) were determined. Specific mRNA expression was calculated relative to
36B4, which was used as an internal control due to its resistance to glucose-dependent regula-
tion [22]. Amplification of specific transcripts was confirmed by melting curve profiles at the
end of each PCR. Expression levels are determined relative to endogenous control. All values
are expressed as mean ± SEM if not indicated otherwise. Results from at least three experi-
ments are shown. ForWestern Blot analysis 3T3-L1 adipocyte cultures were lysed by ultrasoni-
cation in 60 mM Tris-HCl, pH 6.8, containing 2% sodium dodecyl sulfate (SDS) and 10%
sucrose. Cell lysates were diluted 1:1 in sample buffer (250 mM Tris-HCl, pH 6.8, containing
4% SDS, 10% glycerol, and 2% b-mercaptoethanol) and denatured at 95°C for 5 min. Protein
concentration was assessed with the BCA protein assay (Pierbo Science, Bonn, Germany). Pro-
teins (15 μg per lane) were separated by electrophoresis on a 12.5% SDS-polyacrylamide gel
and transferred to nitrocellulose by electroblotting. Nonspecific binding sites were blocked
with 5% dry milk for 45 min, then subsequently incubated with primary antibodies: mouse
anti-adiponectin (Millipore Corporation, Billerica, MA; 1:2,000) and rabbit anti-phospho-
PI3K (Phosphoinositide 3-kinase) (New England Biolabs GmbH, Frankfurt, Germany; 1:2000)
at 4°C overnight. Proteins for detection of glucocorticoid receptor (anti-glucocorticoid-recep-
tor, Glur, abcam, Cambridge, UK; 1:50,000) and estrogen receptor (anti-estrogen-receptor,
Esr1, Abcam, Cambridge, UK; 1:500) were isolated from mouse adipose tissue and nonspecific
binding sites were blocked with 5% bovine serum albumin (BSA) for 60 min. All proteins were
detected by incubating with HRP conjugated secondary antibodies at a 1:3,000 dilution, (Dia-
nova) at RT for 2 h and chemiluminescence kit (Amersham, Pharmacia, Freiburg, Germany).
Integrated optical densities of the immunoreactive protein bands were measured with Gel Ana-
lyzer software (Media Cyberneties, Silver Spring, MD).
Subcutaneous (SC) and visceral adipose tissue was removed and homogenized with tissue-
mill homogenizer (MM400Retsch GmbH, Haan, Germany) in RIPA buffer. Further proce-
dures were performed as previously described [20] with antibodies raised against Peroxisome
proliferator-activated receptor gamma (Ppary, 1:1.000, Cell Signaling Technology,#2430, Dan-
vers, USA) and Adiponectin (Adiponectin, 1:1.000, Cell Signaling Technology,#2789, Danvers,
USA). Equal protein loading was verified using mouse anti-D-glyceraldehyde-3-phosphate
dehydrogenase antibody (GAPDH, Research Diagnostics, Flanders, The Netherlands; 1:3,000).
Bromodeoxyuridine (BrdU) incorporation
BrdU incorporation was assessed in 3T3-L1 preadipocytes grown on glass coverslips. Cells
were induced to differentiate for 24h, and then incubated with 10μM BrdU for 3h. Cells were
fixed with ice-cold methanol for 10min. Fixed cells were incubated with 2M HCl for 1h at 37°C
for DNA denaturation and then neutralized with 0.1M borate buffer (pH 8.5) for 15min.
BrdU-labeled cells were visualized using an anti-BrdU antibody (Biomeda, Foster City, CA)
and an Alexa Fluor1 488 anti-mouse antibody (Invitrogen, Carlsbad, CA). BrdU-positive cells
of 10 randommicroscopic fields were counted for each slide. BrdU staining for each sample
were performed in triplicate.
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Statistics
Results are shown as mean ± SD unless stated otherwise. Differences between various treat-
ments were analyzed by Student´s t tests. P values<0.05 were considered to be statistically
significant.
Results
In vivo DEHP treatment causes increased body weight and alters insulin
tolerance in female mice
Female 129S6 mice treated with DEHP for 10 weeks showed a significantly greater weight gain
and developed impaired insulin sensitivity (Fig 1A and 1B). In contrast, body weight dynamic
and insulin sensitivity was not affected by DEHP in male 129S6 mice (Fig 1A and 1B). To fur-
ther elucidate the body weight differences in females mice, we performed whole body composi-
tion analysis (fat mass, lean mass) in awake female mice by using nuclear magnetic resonance
technology with EchoMRI700™ instrument. As shown in Fig 1, fat mass was significant higher
and lean mass significant decreased in DEHP treated mice compared to control mice (Fig 1C
and 1D). In addition, daily food intake was indistinguishable between female controls and
female DEHP treated mice over the entire 10 weeks treatment period (data not shown), as well
as in weeks 5 and 6 (Fig 1E). There was also no difference in daily food intake in male DEHP
treated (0.17±0.06g/kg body weight/day) or control (0.18±0.05g/kg body weight/day) mice
(p = 0.93). Impaired insulin tolerance in female DEHP treated mice was associated with a sig-
nificant decrease in circulating adiponectin levels (Fig 1G), but no significant differences in
fasted serum insulin or glucose levels (Table 1) compared with control mice. Despite indication
of insulin resistance in the ipITT (Fig 1B) of female mice treated with DEHP, HOMA-IR and
serum triglyceride concentrations did not reflect impaired insulin sensitivity in unchallenged
fasted animals (Table 1).
Moreover, we found significantly reduced Pparg and adiponectin protein levels in SC adi-
pose tissue of DEHP treated mice compared with control mice (Fig 1K, 1L and 1M).
To further elucidate potential mechanisms of increased body weight gain and fat mass in
female 129S6 mice, we measured expression of estrogen receptor (Esr1) and glucocorticoid
receptor (Glur) in subcutaneous (SC) and epigonadal (visceral) adipose tissue (Fig 1J). Impor-
tantly, higher DEHP exposure was associated with significantly 8-fold elevated Esr1 protein
levels in both, SC and visceral adipose tissue compared to controls (p<0.01) (Fig 1I and 1M). A
similar, but not significant trend towards higher expression upon DEHP exposure was
observed for the glucocorticoid receptor (Fig 1J and 1M). Circulating serum estrogen (Fig 1H)
and progesterone (Table 1) levels were decreased in DEHP treated mice. Serum triglycerides,
cholesterol and serum glycerol levels (Table 1) were not affected by DEHP exposure in female
mice.
Primary transformation products of DEHP are at the same level as
further oxidized DEHPmetabolites
We confirmed a sufficient DEHP administration by detection of DEHP metabolites in urine
(S1 Fig). In contrast to humans, where the secondary oxidation products MEHHP and
MEOHP are tenfold higher abundant, the degradation pattern in mice is different. We observe
similar levels of MEHP, the primary degradation product of DEHP in comparison to MEHHP
and MEOHP. Interestingly, distribution of degradation products are identical for exposed and
control animals, although at a different level (S1 Fig).
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Fig 1. In vivo studies of 129S6mice. (A) Body weight gain during treatment with DEHP (B) Insulin tolerance test of 129S6 mice (N = 8 controls, N = 8 DEHP
treatment) after 6 weeks of DEHP intake (C) fat mass and (D) lean mass as percent of body weight was determined in awake female mice by using nuclear
magnetic resonance technology with EchoMRI700 instrument (Echo Medical Systems, Houston, TX, USA) at the end of observation period (10 weeks). Data
are presented as percentage of total body fat and lean mass from body weight. Results are expressed as means ± SE from at least 5 female animals per
treatment group. (E) Food intake per animal, day and body weight calculated from food intake and body weight measurements in weeks 5 and 6 of treatment.
(F) ipGTT was performed on 4-h-fasted after 8 weeks of DEHP treatment in female mice. Results are expressed as means ± SE from at least 5 female
animals per treatment group. (G) Serum adiponectin and (H) estrogen concentrations were analyzed at the end of observation period (10 weeks) in female
DEHP and Adipocyte Function
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The serummetabolome profile indicates significant changes in lipids and
carnitines after DEHP exposure
Overall distribution of metabolites is shown in the volcano plot (Fig 2A and S1 Table), indicat-
ing a general shift towards higher mean values for many lipids and carnitines. We found a clear
trend both for lipids and carnitines, that the unsaturated forms are increased, whereas the satu-
rated forms are not changed or even downregulated by DEHP exposure. As an example, the
acyl-acyl forms of phosphatidylcholines containing 38 carbon atoms in their fatty acid chain
are shown in more detail in Fig 2B. Similar behavior was found for carnitines and acyl-ethyl
forms of phospholipids. DEHP treatment led to lowering of aspartate and kynurenine, but not
ADMA and ornithine (Fig 2B).
DEHP treatment enhances the proliferation of 3T3-L1 cells, but reduces
cellular lipid content
To clarify in more detail the body composition changes under DEHP treatment, we performed
in vitro analysis in 3T3-L1 cells. The BrdU incorporation study revealed a significant difference
in the number of cells to incorporate BrdU between the control and DEHP treated 3T3-L1 cells
in the mitotic clonal expansion phase (Fig 3A and 3B). BrdU incorporation was significantly
elevated in DEHP treated cells indicating an enhanced proliferation rate (Fig 3). Mature
3T3-L1 cells treated with DEHP had lower cellular lipid content (Fig 3C and 3D).
Basal glucose uptake is increased in DEHP treated 3T3-L1 cells
Treatment of 3T3-L1 cells with DEHP resulted in significantly increased basal glucose uptake
and resistance to insulin stimulated glucose incorporation, suggesting that DEHP causes
impaired insulin sensitivity at the cellular level (Fig 3E and 3F).
To investigate whether reduced cellular lipid content in response to DEHP treatment are
explained by reduced fatty acid transport into adipocytes, we performed in vitro fatty acid
uptake experiments. At day 8, control and DEHP treated 3T3-L1 adipocytes were starved
mice (n = 5 per treatment group). Data are presented as mean ± SE from at least 5 female animals per treatment group. (I)Western Blot quantification of
estrogen receptor protein expression (Esr1), (J) glucocorticoid receptor (Glur), Adiponectin (K) and Ppary (L) in subcutaneous (SC) and visceral adipose
tissue of female 129S6 mice (at least n = 3 per experimental group). (M) Representative images in adipose tissue of control and DEHP treated mice. Equal
protein loading was verified using mouse anti-D-glyceraldehyde-3-phosphate dehydrogenase (Gapdh) antibody. The different degrees of significance (t-test
with Welch correction) were indicated as follows in the graphs. *p<0.05; ** p< 0.01.
doi:10.1371/journal.pone.0143190.g001
Table 1. Phenotype of DEHP treated female 129S6 and control animals (n = 5 per group). Data obtained after 10 weeks of treatment are given as
mean ± SEM.
Parameter Control DEHP p-value
Fasting plasma glucose (mmol/l) 4.3 ± 0.1 4.3 ± 0.2 0.92
Fasting plasma insulin (ng/ml) 0.34 ± 0.04 0.46 ± 0.08 0.26
HOMA-IR 0.82 ± 0.15 1.07 ± 0.19 0.42
C-peptide (pmol/l) 705 ± 30 741 ± 24 0.36
Adiponectin (ng/ml) 107.7 ± 7.0 77.6 ± 9.9 0.03
Triglycerides (mmol/l) 1.5 ± 0.3 1.2 ± 0.1 0.11
Total Cholesterol (mmol/l) 2.5 ± 0.1 2.7 ± 0.1 0.22
Glycerol (nmol/ml) 681 ± 96 579 ± 34 0.27
Progesterone (ng/ml) 2.7 ± 0.3 6.7 ± 2.2 0.10
Estrogen (pg/ml) 11.7 ± 4.0 2.2 ± 0.8 0.06
doi:10.1371/journal.pone.0143190.t001
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Fig 2. Serummetabolome profile indicates significant changes in lipids and carnitines. (A) Volcano
plot (fold-change vs significance) of the comparison between metabolites of the exposed group and the
control group of female 129S6mice. The color code for different analyte classes is shown. (B) Box-and-
whisker plot of selected metabolites. Medians, interquartile ranges (boxes) as well as minimal and maximal
values (whiskers) are indicated. Significant differences between metabolites are marked with: *p<0.05, **
p<0.01, *** p<0.001, **** p<0.0001.
doi:10.1371/journal.pone.0143190.g002
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Fig 3. DEHP treatment causes enhanced proliferation rate, reduces lipid content, altered uptake of 2-deoxy-D [14C] glucose and similar palmitic
acid uptake into 3T3-L1 adipocytes. (A) BrdU incorporation in 3T3-L1 adipocytes. BrdU incorporation was assessed in 3T3-L1 preadipocytes grown on
glass coverslips. Cells were induced to differentiate for 24 h, and then incubated with 10 μMBrdU for 3 h. (B) BrdU staining- BrdU-labeled cells were
visualized using an anti-BrdU antibody and an Alexa Fluor1 488 anti-mouse antibody (C) Triglyceride content in mature 3T3-L1 cells (D)Oil Red O staining
of 3T3-L1 adipocytes reveals reduced number of lipid droplet containing cells. 3T3-L1 cells were stained 8 days after induction (magnification 200x). (E)
Basal and insulin stimulated uptake of 2-deoxy-D [14C] glucose was significantly increased in 3T3-L1 cells treated with DEHP. (F) Palmitic acid uptake in
mature adipocytes with and without DEHP treatment. ** p<0.01, *** p<0.001.
doi:10.1371/journal.pone.0143190.g003
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overnight and incubated with 14C-labeled palmitate. However, we did not find differences in
palmitate uptake between DEHP treated cells compared to controls (Fig 3F).
Altered gene and protein expression profile in the DEHP treated
adipocytes
The expression analysis of key adipocyte genes revealed a significant suppression of adiponec-
tin and elevation of phosphoinositol 3-kinase (Pi3k), insulin like growth factor receptor 1
(Igf1r) as well as vesicle-associated membrane protein 4 (Vamp4). Western blot analysis con-
firmed the adiponectin and phospho-Pi3k differences at the protein level (Fig 4A and 4B).
Discussion
Phthalates are synthetic chemicals and ubiquitous environmental contaminants, to which
humans are easily exposed, e.g. by leaching from food packaging materials [23]. DEHP is the
most abundant phthalate in the environment [24]. Humans are exposed to these compounds
through ingestion, inhalation and dermal exposure throughout their entire life. Although they
are readily degraded, phthalates can cross the placenta and DEHP is consistently found in
higher concentrations in children than in adults [1,3]. Strong evidence from experimental ani-
mal studies suggests that DEHP has many adverse effects on the nutritional and metabolic
state [25]. In order to avoid a potential bias of body fat accumulation on impaired glucose
homeostasis and insulin sensitivity in more obesity prone mouse models, we selected 129S6
mice—an obesity resistant mouse model—to study the effects of Di-(2-ethylhexyl)-phthalate
on metabolism and adipose tissue function in vivo.
In the present work, we show that the effects of DEHP exposure on increasing body weight
and body fat mass are female specific and independent of food intake. DEHP treatment and/or
higher fat mass were associated with higher estrogen receptor (Esr1) expression in adipose tis-
sue and a non-significant trend for lower circulating estrogen levels. Our results support data
from a recent study in which DEHP induced estrogen receptor-α expression in a dose-depen-
dent manner in human endometrial stromal cells in vitro [26]. However, it is unlikely that
increased Esr1 expression in AT contributes to higher fat mass in DEHP treated mice, because
mice lacking the ESR1 gene have more adipose tissue compared to wildtype mice [27] and
human studies suggest an inverse relationship between AT Esr1 expression and BMI [28]. In
humans, it has been further demonstrated that low adipose tissue ESR1 levels attenuate cate-
cholamine resistance in SC fat cells of obese women thereby contributing to loss of SC and gain
of visceral fat [29]. We confirm previous in vitro data that DEHP may cause reduced estradiol
levels in mice [30].
Estrogens are recognized as key regulators of energy balance and glucose homeostasis since
estrogen deficiency promotes visceral adiposity and insulin resistance in menopausal women
[31]. Moreover, in experimental animals bilateral ovariectomy induces adipose tissue accumu-
lation and glucose intolerance—a phenoptype, which can be prevented or reversed by 17β-
estradiol treatment [32, 33]. The observed trend for reduced circulating estrogen levels in our
study may therefore at least contribute to higher fat mass and impaired insulin tolerance in
female mice and explain the sexual dimorphism in DEHP effects. Further studies are necessary
to define the precise mechanisms how DEHP may cause decreased estrogen serum concentra-
tions and increased AT estrogen receptor expression.
Interestingly, there was also a non-significant trend for higher Glur protein levels in AT
after DEHP exposure. We cannot exclude that the effects of DEHP treatment on AT accumula-
tion and changes in AT biology are mediated through enhanced glucocorticoid action. Gluco-
corticoid action on target tissues depends on circulating hormone levels, hormone-receptor
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Fig 4. mRNA level and protein expression in mature 3T3-L1 adipocytes.mRNA expression of key genes
(A) in adipose tissue function was performed using RT-PCR. (B)Western Blot analysis of adiponectin and
phospho-phosphoinositol 3-kinase (Pi3-k) and quantification of protein level. * p<0.05, ** p<0.01
doi:10.1371/journal.pone.0143190.g004
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interaction and intracellular prereceptor metabolism [34]. Increased sensitivity of AT to
endogenous glucocorticoids may underly the observed AT phenotype in our study and requires
further mechanistic studies. Noteworthy, we did not measure glucocorticoid serum concentra-
tions upon DEHP treatment.
We further detected significantly lower circulating adiponectin and a significant down-reg-
ulation of Pparg and adiponectin in adipose tissue of DEHP treated mice. Lower adipose tissue
adiponectinmRNA expression corresponds with lower protein level suggesting that DEHP
may cause alterations in insulin sensitivity by reducing adiponectin expression. The phenotype
of DEHP treated female 129S6 mice with higher body weight, fat mass and altered serum
metabolites could be at least in part due to altered adipose tissue function, changes in adipokine
secretion with reduced circulating adiponectin and down-regulation of Pparg.
Our data that DEHP reduces Pparg expression in subcutaneous adipose tissue are in con-
trast with a recent study [12]. Different mouse models (C3H/N in [12] versus 129S6 mice in
our study) and differences in the DEHP exposure may explain these divergent data. Phthalate
metabolites are known ligands to PPARs [7], receptors known to influence glucose homeosta-
sis, impairments in PPAR-signaling pathways are most likely to contribute to the actions of
phthalates on glucose metabolism and diabetes development. Both molecules, adiponectin and
Pparg, are known to protect from insulin resistance and decreased adiponectin serum concen-
trations have been shown to be closely associated with insulin resistance in humans [35].
Because reduced adiponectin serum concentrations reflect adipose tissue dysfunction and may
at least contribute to impaired whole body insulin sensitivity [36, 37], we provide now further
evidence for a causality chain between DEHP treatment-induced adipose tissue dysfunction
and impaired insulin sensitivity—at least suggested by insulin tolerance tests. However, fasting
insulin, glucose, triglyceride serum concentrations as well as glucose tolerance and HOMA-IR
were not significantly affected by DEHP treatment. Since all of these parameters showed a
trend towards alterations consistent with impaired insulin sensitivity, we cannot exclude that
the number of studied animals (n = 5) was too low to unravel significant DEHP effects on addi-
tional parameters of insulin resistance and impaired glucose metabolism. Due to the study size
restriction provided by the local animal ethics review board, we could not increase the number
of animals in the context of this study. Therefore, further studies, including a higher number of
experimental animals and maybe using more sophisticated methods to assess insulin sensitivity
such as euglycemic-hyperinsulinemic clamps should be performed.
Recently, studies in male albino Wistar rats suggested that DEHP induces insulin resistance
in adipose tissue via increased reactive oxygen species production and lipid peroxidation that
disrupts insulin signaling in adipose tissue and favors glucose intolerance [38]. We did not
measure oxidative stress markers in adipose tissue of our mouse model and can therefore not
exclude the proposed mechanism by Rajesh et al. [38]. Moreover, we did not detect an effect of
DEHP treatment on body weight and increased fat mass in male 129S6 mice. In addition to the
observed effects of DEHP on impaired insulin tolerance, we cannot exclude a DEHP effect on
impaired beta cell function in female mice. Potential effects of chronic DEHP treatment on
beta cells may be suggested by a trend of higher 30 and 60min glucose concentrations in
response to the intraperitoneal glucose challenge (Fig 1F).
To further explore whether DEHP may have additional effects on circulating parameters of
metabolism, we performed serum metabolomics studies. We found that DEHP treatment was
associated with significantly higher serum concentrations of phosphatidylcholine diacyls
(PCaa 38:3, PCaa 38:4, PCaa 38:5, PCaa 38:6) and significantly lower concentrations of phos-
phatidylcholine diacyl 38:1 and the amino acids aspartic acid and kynurenine. In general, we
found a shift towards higher mean values for several phospholipids and carnitines, specifically
the higher unsaturated molecule species: acyl-acyl and acyl-ethyl phospholipids and carnitines.
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These metabolites are known to be secreted into the circulation by adipose tissue and have
been associated with the loss of body fat in a humans undergoing bariatric surgery [39]. More-
over, in genetically obese mice, phosphatidylcholine diacyls C38:4 and C38:5 have been
recently found to be significantly lower compared to lean control mice [40]. These data seem to
be in part contradictory to our metabolomics results, particularly since DEHP treated mice had
significantly higher fat mass compared to controls at the time point of metabolite analyses.
Based on the metabolite profile differences between our study and previous reports [39, 40], we
hypothesize that DEHP may alter serum concentrations of distinct phospholipids and carni-
tines via adipose tissue independent mechanisms.
Several phospholipids and carnitines have been described to be regulated in an age and/or
gender dependent manner in humans [41]. However, one limitation of our study is that we
were not able to adjust for potential gender and age effects.
In contrast to previous rat DEHP exposure studies, we found a decrease of aspartate upon
DEHP treatment, suggesting that the effects of DEHP maybe species specific [42]. Kynurenine
serum concentrations are significantly lower upon DEHP treatment and its associated higher
fat mass in our study. In contrast to these data, human studies found consistently higher kynur-
enine concentrations in individuals with obesity and type 2 diabetes [43, 44, 45, 46]. These
divergent findings suggest that DEHP induced increase in fat mass may cause different alter-
ations in the circulating metabolome than AT accumulation caused by other mechanism.
We further sought to define the effects of DEHP on adipose tissue in an in vitromodel, the
3T3-L1 cells. In this model system, we demonstrate that the plasticizer DEHP has significant
enhancing effects on adipocyte proliferation, but reduces cellular lipid content. These results
confirm previous findings that DEHP elevates the proliferation rate in the hepatocyte cell line
(HepG2) and extend it to an adipocyte model [46]. Recently, Chen et al. (2013) provided exper-
imental evidence that activation of the PI3K-AKT-mTOR signaling pathway promotes DEHP-
induced proliferation in Hep3B cells [47]. In accordance with these data, we find significant
activation of phosphoinositide 3-kinase in 3T3L1 cells induced by DEHP in vitro. We therefore
hypothesize that increased proliferation of 3T3L1 cells may be induced by activation of the
PI3K signaling pathway. Our data further support previous findings that DEHP promotes adi-
pogenic differentiation of murine mesenchymal stem cells (MSC, C3H/10T1/2) [48]. At the
organism level, theoretically higher energy demand for increased adipose tissue proliferation
upon DEHP treatment may be covered by reduced lean body mass.
We found that DEHP exposure led to significantly decreased cellular lipid content in
3T3-L1 cells. In principle, reduced lipid droplet size in adipocytes could be due to decreased tri-
glyceride synthesis, decreased glucose or fatty acid uptake and/or increased lipolysis. Surpris-
ingly, both, basal and insulin stimulated glucose uptake were significantly increased by DEHP
in 3T3-L1 cells. This result is in accordance with increased glucose uptake into rat adipocytes
after DEHP stimulation [38]. We further determined palmitic acid incorporation into 3T3-L1
cells by radioactivity assay. Since palmitic acid uptake was not affected by DEHP treatment,
lower lipid content in DEHP-treated 3T3-L1 cells are most likely due to increased lipolysis.
From rat studies it is known that DEHP intake effects lipolysis and LPL activity, with regard to
the potential contribution to the known fat-lowering effect of this plasticizer [49, 50]. However,
we did not measure in vitro lipolysis directly. Importantly, DEHP treatment of 3T3L1 cells in
our study caused cellular changes, which closely resembles the phenotype of 3T3-L1 adipocytes
that overexpress a dominant negative PPARγmutant [51]. Because, DEHP treatment signifi-
cantly downregulated PPARγ in 3T3L1 cells, our data suggest that PPARγ dependent mecha-
nisms underly the observed lower triglyceride content and altered glucose uptake—similar to
that shown for an experimental deletion of PPARγ in 3T3L1 cells [51]. Reduced PPARγ in
3T3L1 cells further caused changes in the abundance of mRNAs for several key enzymes that
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contribute to triglyceride and free fatty acid metabolism as well as the amounts of GLUT4, insu-
lin receptor, insulin receptor substrate (IRS), and C/EBPαmRNAs [51]. Taken together, data
from our 3T3-L1 DEHP treatment studies strongly suggest that reduced PPARγ (and subse-
quent gene expression changes) caused the observed alterations in cellular triglyceride content
and glucose transport.
On the other hand, several other mechanisms could be involved in reduced lipid droplet
size of DEHP treated 3T3-L1 cells. We therefore tested the hypothesis that lipid content alter-
ations are due to changes in vesicle formation. In comparison with control cells, DEHP treated
cells had significant higher vesicle-associated membrane protein 4 (Vamp4) expression, indi-
cating an impaired vesicle formation process [52]. Further studies are required to test the
hypothesis that DEHP directly affects Vamp4 expression. Differences of VAMP4 protein
expression has been recently shown to influence the rate of lipid droplet fusion and the size of
lipid droplets [52]. Transfection of NIH-3T3 cells with Vamp4 siRNA decreased the size of the
lipid droplets and lipid fusion rate [52]. Moreover, we found increased Igf1r expression follow-
ing DEHP treatment of 3T3L1 cells to be associated with smaller lipid droplet size. We previ-
ously demonstrated that conditional IGF-1R inactivation results in increased adipocyte size
and adipose tissue mass suggesting that intact Igf1r signaling in adipocytes maybe important in
the regulation of lipid storage capacity [53]. In the light of these data, we propose that DEHP-
associated increase in Igf1r expression contributes to smaller lipid droplet size in 3T3L1 cells.
Taken together our findings suggest that DEHP may cause adipocyte dysfunction (reflected
by altered adiponectin secretion and decreased Pparg protein expression), which could contrib-
ute to increased fat mass, impaired insulin tolerance and changes to serum metabolites.
Conclusions
In conclusion, our data provide evidence that chronic DEHP treatment causes increased body
weight, fat mass and altered serum metabolites in a gender specific manner, which could be
mediated by a DEHP-induced increase in estrogen receptor expression and reduced Pparg
expression in adipose tissue. Although, DEHP treatment led to significantly impaired insulin
tolerance, it did not affect glucose tolerance, HOMA-IR, fasting glucose, insulin or triglyceride
serum concentrations. This may suggest that DEHP treatment does not cause impaired glucose
metabolism at the whole body level.
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